Evidence map›Paper›PMID 40116434›Full record

ArticleCancer medicine2025

Quantifying the Diagnosis and Survival of Early Onset Bowel Cancer Among First Nations Peoples in Queensland, Australia.

Tsegaw Amare Baykeda, Shafkat Jahan, Kirsten Howard, Rakhee Raghunandan, Gail Garvey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tsegaw Amare BaykedaSchool of Public Health, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-2588-8929
Shafkat JahanSchool of Public Health, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-0447-8664
Kirsten HowardThe Leeder Centre for Health Policy, Economics and Data, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-0918-7540
Rakhee RaghunandanThe Leeder Centre for Health Policy, Economics and Data, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0001-7848-6109
Gail GarveySchool of Public Health, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0001-5065-5716

Funding

Centre of Research Excellence (CRE) in Targeted Approaches To Improve Cancer Services for Aboriginal and Torres Strait Islander Australians GNT#1153027National Health and Medical Research Council GNT 1176651National Health and Medical Research Council GNT 2015290
6 · The paper itself

Abstract

introductionThe incidence of early-onset bowel cancer (EOBC) is increasing in Australia and globally. However, the burden of EOBC among First Nations Australians is rarely determined. This study aimed to quantify the diagnosis and survival rates of EOBC among First Nations Peoples in Queensland, Australia.

methodsCancerCostMod, a linked administrative dataset of patients diagnosed with cancer in Queensland from 1st July 2011 to 30th June 2015, was used. EOBC was defined as a diagnosis of bowel cancer (i.e., colon, rectosigmoid, or rectal cancer) at 18-49 years of age. A multivariable logistic regression analysis was employed to determine the association of Indigenous status and other factors with a diagnosis of EOBC. Five-year survival rates were used to estimate the survival rate.

resultsOf 11,702 bowel cancer cases, 9.2% (95% CI: 8.7%-9.7%) were EOBC, with 19% among First Nations peoples and 9% among Non-First Nations. First Nations Australians had 2.6 times the odds of EOBC diagnosis (95% CI: 1.7-4.0) compared with Non-First Nations Australians. Overall, EOBC patients showed a significantly higher 5-year survival rate of 77% compared with 60% for late-onset bowel cancer patients. However, First Nations EOBC patients showed a lower 5-year survival rate (73%) than Non-First Nations EOBC patients (77%).

conclusionFirst Nations Australians have more than double the diagnosis rates and lower 5-year survival for EOBC compared to Non-First Nations. Whilst the recent lowering of the age eligibility for the National Bowel Cancer Screening Program is a beneficial strategy to address the increasing incidence of EOBC, special consideration should be given to addressing the higher diagnosis rates and lower survival among First Nations Australians. This study raises the potential for further lowering the age eligibility for First Nations Australians to ensure younger First Nations Australians can access screening for earlier detection, thereby improving their survival from bowel cancer.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerAdolescentAdultAge of OnsetAustralian Aboriginal and Torres Strait Islander PeoplesFemaleHumansIncidenceMaleMiddle AgedQueenslandSurvival RateYoung Adultaboriginal and Torres Strait islander peoplesbowel cancerearly onset bowel cancerFirst Nations Indigenous Australiansyoung‐onset bowel cancer

Identifiers

PMID40116434
PMCPMC11926912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.